Home
Drugs
Taxane

Taxane

Drug

Related News

Relacorilant-nab-paclitaxel Improves Survival in Ovarian Cancer Despite Prior Taxane Use

May 30, 2026

The phase 3 ROSELLA trial showed relacorilant plus nab-paclitaxel significantly improved overall survival in platinum-resistant ovarian cancer by 4.1 months versus nab-paclitaxel alone. The benefit was consistent across all subgroups regardless of prior taxane exposure, leading to FDA approval in March 2026. The combination also met its progression-free survival endpoint and demonstrated a favorable safety profile.

T-DXd Reshapes Treatment Sequencing in HER2-Positive Metastatic Breast Cancer

Mar 21, 2026

Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.

Iza-bren Meets Dual Endpoints in Phase III Triple-Negative Breast Cancer Trial

Feb 27, 2026

Izalontamab brengitecan demonstrated statistically significant improvements in progression-free survival and overall survival compared to chemotherapy in patients with previously treated metastatic triple-negative breast cancer, marking the third Phase III success for the bispecific ADC.

Enhertu Plus Pertuzumab Approved for First-Line HER2+ Metastatic Breast Cancer

Feb 24, 2026

Enhertu combined with pertuzumab received FDA approval for first-line treatment of HER2-positive metastatic breast cancer, marking the first new treatment in a decade. Real-world data show trastuzumab deruxtecan efficacy is consistent across patient subgroups.

HER2-Positive Breast Cancer Treatment Advances in First-Line and Neoadjuvant Settings

Feb 17, 2026

New clinical trial data show trastuzumab deruxtecan plus pertuzumab extends progression-free survival as first-line therapy, while MRI-guided treatment shortening reduces toxicity in neoadjuvant settings for HER2-positive breast cancer.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07158918	ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors	RECRUITING	PHASE1/PHASE2
NCT06102824	Organoid-based Functional Precision Therapy for Advanced Breast Cancer	RECRUITING	PHASE2
NCT04920747	Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients	COMPLETED
NCT04784715	Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)	ACTIVE_NOT_RECRUITING	PHASE3
NCT04293393	Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients	ACTIVE_NOT_RECRUITING	PHASE2
NCT03393741	Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy	TERMINATED
NCT02685306	A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer	WITHDRAWN	PHASE2
NCT02651610	Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer	WITHDRAWN	PHASE2/PHASE3
NCT02624531	Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)	RECRUITING	NA
NCT02489903	RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)	COMPLETED	PHASE2